Abstract
Primary Sjögren's Syndrome (pSS) is an autoimmune disease that mostly affects women. Patients with pSS experience dry mouth and eyes in addition to signs of systemic disease. pSS was considered a Th1 autoimmune disease for many years. However, in various studies, it has been shown that dysregulation of regulatory cells play critical role in the pathogenesis of the disease. This review focuses on studies supporting this view and answers questions about the role of regulatory cells in the pathogenesis of pSS.
Publisher
Journal of Health Sciences and Medicine
Reference42 articles.
1. Du W, Han M, Zhu X, et al. The multiple roles of b cells in the pathogenesis of Sjögren's syndrome. Front Immunol 2021; 12: 684999.
2. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013; 9: 544–56.
3. Srivastava A., Makarenkova HP. Innate immunity and biological therapies for the treatment of Sjögren's syndrome. Int J Mol Sci 2020; 21: 9172.
4. Uptodate, https://www.uptodate.com/contents/overview-of-the-management-and-prognosis-of-sjogrens- syndrome?search=sjogren%20treat. Baer NA, Vivino FB. 30 July 2021.
5. Negrini S, Emmi G, Greco M, et al. Sjögren's syndrome: a systemic autoimmune disease. Clin Exp Med 2022; 22: 9–25.